Table 6. Follow-up cytogenetic studies... | American Society of Hematology

Table 6.

Follow-up cytogenetic studies among patients with improved cytogenetic response on PEG IFN-α-2b

Patient	Percent Ph⁺ metaphases on PEG IFN-α-2b therapy
Patient	Pretreatment	Best (overall)	At 3 months	At 6 months	At 9 months	At 12 months	After 12 months [month of therapy]
9	100	0	—	95	95	100	65 [18], 40 [26], 0 [30]
13	15	0	10	10	0	15	0 [14], 30 [17], 10 [20], 65 [24], 25 [26]
14	100	0	100	95	95	75	55 [15], 0 [25]
15	50	0	60	40	30	13	0 [16], 25 [25]
17	50	0	0	0	0	0	0 [16], 0 [24]
20	30	5	14	5	35	Insufficient	10 [13], 30 [17], 45 [24]
23	20	0	15	0	0	0	5 [19]
25	69	17 (1 mo)	90	90	100	—	—
27	75	25	75	47	25	—	25 [21]

Patient	Percent Ph⁺ metaphases on PEG IFN-α-2b therapy
Patient	Pretreatment	Best (overall)	At 3 months	At 6 months	At 9 months	At 12 months	After 12 months [month of therapy]
9	100	0	—	95	95	100	65 [18], 40 [26], 0 [30]
13	15	0	10	10	0	15	0 [14], 30 [17], 10 [20], 65 [24], 25 [26]
14	100	0	100	95	95	75	55 [15], 0 [25]
15	50	0	60	40	30	13	0 [16], 25 [25]
17	50	0	0	0	0	0	0 [16], 0 [24]
20	30	5	14	5	35	Insufficient	10 [13], 30 [17], 45 [24]
23	20	0	15	0	0	0	5 [19]
25	69	17 (1 mo)	90	90	100	—	—
27	75	25	75	47	25	—	25 [21]